You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 021283

✉ Email this page to a colleague

NDA 021283 describes DIOVAN, which is a drug marketed by Novartis and is included in three NDAs. It is available from two suppliers. Additional details are available on the DIOVAN profile page.

The generic ingredient in DIOVAN is hydrochlorothiazide; valsartan. There are thirty-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.

Summary for 021283

Tradename:	DIOVAN
Applicant:	Novartis
Ingredient:	valsartan
Patents:	0

Pharmacology for NDA: 021283

Mechanism of Action	Angiotensin 2 Receptor Antagonists

Medical Subject Heading (MeSH) Categories for 021283

Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents

Suppliers and Packaging for NDA: 021283

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
DIOVAN	valsartan	TABLET;ORAL	021283	NDA	Novartis Pharmaceuticals Corporation	0078-0358	0078-0358-34	90 TABLET in 1 BOTTLE (0078-0358-34)
DIOVAN	valsartan	TABLET;ORAL	021283	NDA	Novartis Pharmaceuticals Corporation	0078-0359	0078-0359-34	90 TABLET in 1 BOTTLE (0078-0359-34)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	80MG
Approval Date:	Jul 18, 2001	TE:	AB	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	160MG
Approval Date:	Jul 18, 2001	TE:	AB	RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	320MG
Approval Date:	Jul 18, 2001	TE:	AB	RLD:	Yes

Expired US Patents for NDA 021283

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-002	Jul 18, 2001	⤷ Get Started Free	⤷ Get Started Free
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-003	Jul 18, 2001	⤷ Get Started Free	⤷ Get Started Free
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-004	Aug 14, 2002	⤷ Get Started Free	⤷ Get Started Free
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-002	Jul 18, 2001	⤷ Get Started Free	⤷ Get Started Free
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-002	Jul 18, 2001	⤷ Get Started Free	⤷ Get Started Free
Novartis	DIOVAN	valsartan	TABLET;ORAL	021283-001	Jul 18, 2001	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.